Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Carcinoma, Renal Cell
- Main trialPhase 1/2
- “A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy. All participants must have end-stage kidney disease and be receiving stable chronic hemodialysis.”In the company’s words, NCT05287945 on ClinicalTrials.gov
Other drugs for Carcinoma, Renal Cell
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- BelzutifanMerck & Co. · Phase 3
- AbexinostatXynomic Pharmaceuticals, Inc. · Phase 3
- DurvalumabAstraZeneca · Phase 3
- IpilimumabBristol Myers Squibb · Phase 3
- NivolumabBristol Myers Squibb · Phase 3
Coming up1
- 31 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Dec 2027 | Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026